Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Tumour Immunology

LAP targeting reduces tolerogenic cells in cancer

Nature Reviews Immunology volume 17, pages 402–403 (2017)Cite this article

Subjects

The authors were particularly interested in targeting LAP+ TGFβ+ FOXP3+ T cells, a highly immunosuppressive subset of Treg cells that are upregulated in human malignancies. These cells express LAP and TGFβ, which are encoded by the same gene (TGFB1), as a small latent complex on their cell surface, in which LAP keeps TGFβ in its inactive form. TGFβ has multiple roles in cancer: it can increase tumour cell proliferation and invasion, induce angiogenesis, affect the maturation of antigen-presenting cells and promote immunosuppression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gabriely, G. et al. Targeting latency-associated peptide promotes antitumor immunity. Sci. Immunol. 2, eaaj1738 (2017)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Authors
  1. Alexandra Flemming
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Flemming, A. LAP targeting reduces tolerogenic cells in cancer. Nat Rev Immunol 17, 402–403 (2017). https://doi.org/10.1038/nri.2017.65

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nri.2017.65

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer